VEGFB and metabolic syndrome: Under streptozotocin (STZ)-induced diabetes, Vegfb<sup>KO</sup> rats exhibited increased cardiac LPL activity, protecting animals from dyslipidemia, decreased plasma saturated FA, and provided a safer cardiac FA source, LPL-derived FA.